Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly ...

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at $35 per month.  The Novo Nordisk settlement reached on Jan. 27 ...

Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

In Massachusetts, the Legislature recently passed a bill putting PBMs under the state’s health care cost trends hearing ...

Tradjenta is an oral diabetes medicine that ... may adjust them over time. The process targets high-cost, brand-name drugs without competition. Shares of Eli Lilly were already in an intermediate ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.